NASDAQ:TWST

Twist Bioscience Competitors

$116.74
+12.44 (+11.93 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$112.14
$120.87
50-Day Range
$104.30
$142.06
52-Week Range
$34.16
$214.07
Volume1.62 million shs
Average Volume947,216 shs
Market Capitalization$5.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.83

Competitors

Twist Bioscience (NASDAQ:TWST) Vs. TECH, ARGX, NVAX, QGEN, RGEN, and NBIX

Should you be buying TWST stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Twist Bioscience, including Bio-Techne (TECH), argenx (ARGX), Novavax (NVAX), QIAGEN (QGEN), Repligen (RGEN), and Neurocrine Biosciences (NBIX).

Bio-Techne (NASDAQ:TECH) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares Bio-Techne and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Twist Bioscience-155.31%-44.62%-35.49%

Valuation and Earnings

This table compares Bio-Techne and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million22.22$229.30 million$3.86109.60
Twist Bioscience$90.10 million63.03$-139,930,000.00($3.00)-38.91

Bio-Techne has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Bio-Techne and Twist Bioscience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne03702.70
Twist Bioscience11302.40

Bio-Techne presently has a consensus price target of $396.1111, suggesting a potential downside of 6.37%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Bio-Techne.

Insider and Institutional Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by insiders. Comparatively, 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

Bio-Techne beats Twist Bioscience on 11 of the 14 factors compared between the two stocks.

argenx (NASDAQ:ARGX) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares argenx and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
argenxN/AN/AN/A
Twist Bioscience-155.31%-44.62%-35.49%

Valuation and Earnings

This table compares argenx and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$78.17 million173.08$-182,520,000.00($4.73)-55.75
Twist Bioscience$90.10 million63.03$-139,930,000.00($3.00)-38.91

Twist Bioscience has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for argenx and Twist Bioscience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
argenx081002.56
Twist Bioscience11302.40

argenx presently has a consensus price target of $292.8750, suggesting a potential upside of 11.06%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than argenx.

Insider and Institutional Ownership

54.2% of argenx shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

argenx has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Novavax (NASDAQ:NVAX) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares Novavax and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Twist Bioscience-155.31%-44.62%-35.49%

Valuation and Earnings

This table compares Novavax and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million698.82$-132,690,000.00($5.80)-30.34
Twist Bioscience$90.10 million63.03$-139,930,000.00($3.00)-38.91

Novavax has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Novavax and Twist Bioscience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax10602.71
Twist Bioscience11302.40

Novavax presently has a consensus price target of $229.6429, suggesting a potential upside of 30.48%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Novavax is more favorable than Twist Bioscience.

Insider and Institutional Ownership

49.9% of Novavax shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 3.3% of Novavax shares are owned by insiders. Comparatively, 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Novavax has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

QIAGEN (NYSE:QGEN) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for QIAGEN and Twist Bioscience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN05902.64
Twist Bioscience11302.40

QIAGEN presently has a consensus price target of $60.76, suggesting a potential upside of 27.54%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given QIAGEN's stronger consensus rating and higher possible upside, analysts clearly believe QIAGEN is more favorable than Twist Bioscience.

Insider and Institutional Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by insiders. Comparatively, 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares QIAGEN and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
Twist Bioscience-155.31%-44.62%-35.49%

Valuation and Earnings

This table compares QIAGEN and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion7.12$-41,460,000.00$1.4333.31
Twist Bioscience$90.10 million63.03$-139,930,000.00($3.00)-38.91

QIAGEN has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

QIAGEN has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

QIAGEN beats Twist Bioscience on 11 of the 14 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Twist Bioscience and Repligen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Twist Bioscience11302.40
Repligen00503.00

Twist Bioscience presently has a consensus target price of $137.50, suggesting a potential upside of 17.78%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 18.61%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Twist Bioscience.

Insider & Institutional Ownership

87.9% of Twist Bioscience shares are held by institutional investors. Comparatively, 84.3% of Repligen shares are held by institutional investors. 7.0% of Twist Bioscience shares are held by insiders. Comparatively, 1.7% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Twist Bioscience and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Twist Bioscience-155.31%-44.62%-35.49%
Repligen13.40%6.58%5.00%

Earnings & Valuation

This table compares Twist Bioscience and Repligen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$90.10 million63.03$-139,930,000.00($3.00)-38.91
Repligen$270.24 million38.15$21.41 million$1.07175.51

Repligen has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Twist Bioscience has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Summary

Repligen beats Twist Bioscience on 11 of the 14 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Twist Bioscience and Neurocrine Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Twist Bioscience11302.40
Neurocrine Biosciences071302.65

Twist Bioscience presently has a consensus target price of $137.50, suggesting a potential upside of 17.78%. Neurocrine Biosciences has a consensus target price of $127.8333, suggesting a potential upside of 40.41%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Twist Bioscience.

Insider & Institutional Ownership

87.9% of Twist Bioscience shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 7.0% of Twist Bioscience shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Twist Bioscience and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Twist Bioscience-155.31%-44.62%-35.49%
Neurocrine Biosciences8.96%18.18%9.50%

Earnings & Valuation

This table compares Twist Bioscience and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$90.10 million63.03$-139,930,000.00($3.00)-38.91
Neurocrine Biosciences$788.10 million10.92$37.01 million$0.39233.44

Neurocrine Biosciences has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Twist Bioscience has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Summary

Neurocrine Biosciences beats Twist Bioscience on 12 of the 14 factors compared between the two stocks.


Twist Bioscience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bio-Techne logo
TECH
Bio-Techne
1.8$423.05+2.9%$16.41 billion$738.69 million67.69Earnings Announcement
Dividend Announcement
Analyst Downgrade
News Coverage
Gap Down
argenx logo
ARGX
argenx
1.3$263.70+2.1%$13.53 billion$78.17 million-55.75Upcoming Earnings
Novavax logo
NVAX
Novavax
1.6$176.00+2.0%$13.04 billion$18.66 million-33.72Upcoming Earnings
Insider Selling
News Coverage
QIAGEN logo
QGEN
QIAGEN
1.7$47.64+0.1%$10.86 billion$1.53 billion58.81Earnings Announcement
Analyst Report
Analyst Revision
Repligen logo
RGEN
Repligen
1.7$187.80+1.4%$10.31 billion$270.24 million229.02Earnings Announcement
Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$91.04+1.8%$8.61 billion$788.10 million97.89Earnings Announcement
Analyst Report
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$107.70+0.1%$8.16 billion$289.59 million-33.04Gap Up
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$76.49+0.1%$7.18 billion$10.68 million-41.57Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.8$118.18+3.1%$7.17 billion$73.99 million-45.63Earnings Announcement
News Coverage
Gap Up
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$47.57+0.3%$6.82 billion$195.99 million297.31Upcoming Earnings
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$54.30+0.6%$6.58 billion$26.68 million-24.57Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Vir Biotechnology logo
VIR
Vir Biotechnology
1.4$42.97+3.2%$5.50 billion$8.09 million-18.21Earnings Announcement
Analyst Downgrade
News Coverage
Kodiak Sciences logo
KOD
Kodiak Sciences
1.7$101.62+0.2%$5.21 billionN/A-43.80Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$34.99+4.6%$4.90 billion$85.07 million-36.83Earnings Announcement
Analyst Upgrade
Insider Selling
Gap Up
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99+1.7%$4.72 billion$503.70 million33.52
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$70.82+1.0%$4.43 billion$20,000.00-5.04Upcoming Earnings
Gap Up
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.9$28.52+0.3%$4.34 billionN/A-14.85Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$30.02+2.8%$4.25 billionN/A-14.09Earnings Announcement
Analyst Revision
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$73.36+3.0%$3.60 billionN/A-42.16Earnings Announcement
News Coverage
Gap Down
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$65.97+2.9%$2.98 billion$125.57 million-38.58Upcoming Earnings
Analyst Downgrade
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$29.50+1.1%$2.67 billionN/A0.00
Vericel logo
VCEL
Vericel
1.1$52.65+0.9%$2.43 billion$117.85 million-5,265,000.00Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$13.12+1.5%$2.33 billion$48.83 million-17.26Earnings Announcement
Analyst Report
News Coverage
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.11+0.7%$2.31 billion$20.53 million-19.60Earnings Announcement
Analyst Revision
Gap Up
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$29.56+1.9%$2.17 billion$50.04 million0.00Upcoming Earnings
Analyst Upgrade
News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.5$26.15+4.2%$2.12 billionN/A-12.22Upcoming Earnings
Gap Down
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.20+2.6%$2.06 billion$31.43 million-4.93Upcoming Earnings
bluebird bio logo
BLUE
bluebird bio
1.8$30.48+2.7%$2.06 billion$44.67 million-2.78Earnings Announcement
Analyst Revision
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.1$44.05+7.0%$1.99 billionN/A0.00Earnings Announcement
Gap Down
Ocugen logo
OCGN
Ocugen
1.0$9.19+4.2%$1.73 billionN/A-6.21Earnings Announcement
Analyst Downgrade
High Trading Volume
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.84+0.9%$1.67 billionN/A-20.25
Immunovant logo
IMVT
Immunovant
1.6$16.76+1.6%$1.64 billionN/A-12.99
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$70.78+0.5%$1.57 billionN/A-47.82Upcoming Earnings
Analyst Downgrade
AlloVir logo
ALVR
AlloVir
1.5$23.85+6.2%$1.55 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.6$36.27+4.4%$1.54 billion$35.23 million-14.62Earnings Announcement
News Coverage
Gap Down
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.54+1.3%$1.52 billion$102.43 million-17.57Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$34.28+3.1%$1.48 billionN/A0.00Gap Down
Translate Bio logo
TBIO
Translate Bio
1.6$19.43+3.6%$1.46 billion$7.80 million-18.16Analyst Revision
News Coverage
Alector logo
ALEC
Alector
1.3$16.35+3.8%$1.30 billion$21.22 million-7.33Earnings Announcement
News Coverage
Gap Up
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.52+1.3%$1.21 billion$100.56 million0.00Upcoming Earnings
Analyst Revision
News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.59+5.2%$1.14 billionN/A-2.94Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Cortexyme logo
CRTX
Cortexyme
1.6$37.10+1.1%$1.10 billionN/A-15.46Upcoming Earnings
News Coverage
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.68+3.6%$1.06 billion$20.49 million-12.73Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.32+1.3%$1.05 billion$356.07 million7.02Earnings Announcement
Analyst Report
News Coverage
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$27.13+0.2%$1.03 billionN/A0.00Upcoming Earnings
Curis logo
CRIS
Curis
1.3$10.25+2.5%$938.07 million$10 million-12.50Upcoming Earnings
Analyst Revision
Passage Bio logo
PASG
Passage Bio
1.8$17.29+4.2%$933.26 millionN/A0.00Earnings Announcement
Increase in Short Interest
Analyst Revision
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.50+0.2%$921.52 millionN/A-4.21Earnings Announcement
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$17.64+1.8%$905.90 millionN/A0.00Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$6.98+1.3%$905.58 million$32.16 million-7.93Analyst Revision
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.